Publications by authors named "Markus Warmuth"

54Publications

H3B-6545, a selective estrogen receptor covalent antagonist, prevents bone loss in ovariectomized Sprague-Dawley rats.

J Pharmacol Toxicol Methods 2019 Sep - Oct;99:106595. Epub 2019 Oct 17.

H3 Biomedicine, Inc., Cambridge, MA, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vascn.2019.05.133DOI Listing
October 2019

Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).

Cancer Chemother Pharmacol 2019 01 1;83(1):151-160. Epub 2018 Nov 1.

H3 Biomedicine Inc, 300 Technology Square, Cambridge, MA, 02139, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-018-3716-3
Publisher Site
http://dx.doi.org/10.1007/s00280-018-3716-3DOI Listing
January 2019

Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.

Cancer Chemother Pharmacol 2019 01 27;83(1):91-96. Epub 2018 Oct 27.

H3 Biomedicine Inc, 300 Technology Square, Cambridge, MA, 02139, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-018-3708-3
Publisher Site
http://dx.doi.org/10.1007/s00280-018-3708-3DOI Listing
January 2019

NAMPT is the cellular target of STF-31-like small-molecule probes.

ACS Chem Biol 2014 Oct 7;9(10):2247-54. Epub 2014 Aug 7.

Center for the Science of Therapeutics and ∥Howard Hughes Medical Institute, Broad Institute , 7 Cambridge Center, Cambridge, Massachusetts 02142, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/cb500347pDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201331PMC
October 2014

Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL.

Blood 2012 Jan 30;119(4):997-1007. Epub 2011 Nov 30.

Department of Hematology/Oncology, University Medical Center Freiburg, Hugstetter Strasse 55, Freiburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-06-359075DOI Listing
January 2012

Allosteric inhibition of BCR-ABL.

Cell Cycle 2010 Sep 3;9(18):3710-4. Epub 2010 Sep 3.

Novartis Institute for Biomedical Research, Cambridge, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.9.18.13232DOI Listing
September 2010

Hedgehog pathway activation in chronic myeloid leukemia.

Cell Cycle 2010 Sep;9(17):3449-56

Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.9.17.12945DOI Listing
September 2010

A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.

J Med Chem 2010 Aug;53(15):5439-48

Dana Farber Cancer Institute, Harvard Medical School, Department of Cancer Biology and Department of Biological Chemistry and Molecular Pharmacology, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm901808wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134510PMC
August 2010

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.

Cancer Cell 2008 Sep;14(3):238-49

Department of Hematology/Oncology, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2008.08.003DOI Listing
September 2008

Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies.

Expert Opin Drug Discov 2008 Aug;3(8):959-78

Group Leader Genomics Institute of the Novartis Research Foundation, Department of Kinase Biology, 10675 John J. Hopkins Dr, San Diego, CA 92121, USA +1 858 812 1728 ; +1 858 812 1918 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17460441.3.8.959DOI Listing
August 2008

Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.

Ann Hematol 2008 Mar 25;87(3):183-93. Epub 2007 Oct 25.

Clinical Cooperation Group Gene Therapy, GSF-Research Center for Environment and Health, Marchioninistrasse 25, 81377, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-007-0400-9DOI Listing
March 2008

Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.

Ann Hematol 2007 Nov 1;86(11):777-85. Epub 2007 Aug 1.

Clinical Cooperation Group Gene Therapy, GSF-National Research Center for Environment and Health, Marchioninistr 25, 81377, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-007-0344-0DOI Listing
November 2007

Essential role of stromally induced hedgehog signaling in B-cell malignancies.

Nat Med 2007 Aug 15;13(8):944-51. Epub 2007 Jul 15.

Kinase Biology/In-vivo Oncology, Department of Pharmacology, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nm1614
Publisher Site
http://dx.doi.org/10.1038/nm1614DOI Listing
August 2007

B-Raf kinase inhibitors for cancer treatment.

Curr Opin Investig Drugs 2007 Jun;8(6):452-6

Genomics Institute of the Novartis Research Foundation, Kinase Platform, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
June 2007

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Proc Natl Acad Sci U S A 2007 Jan 21;104(1):270-5. Epub 2006 Dec 21.

Kinase Lead Discovery, Department of Pharmacology, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0609412103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1765448PMC
January 2007

Ba/F3 cells and their use in kinase drug discovery.

Curr Opin Oncol 2007 Jan;19(1):55-60

Kinase Platform and Department of Lead Discovery, Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e328011a25fDOI Listing
January 2007

Profiling the kinome for drug discovery.

Drug Discov Today Technol 2006 ;3(3):269-76

Kinase Drug Discovery, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. Electronic

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ddtec.2006.09.012DOI Listing
July 2014

A general strategy for creating "inactive-conformation" abl inhibitors.

Chem Biol 2006 Jul;13(7):779-86

Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2006.05.015DOI Listing
July 2006

SRC family kinases: potential targets for the treatment of human cancer and leukemia.

Curr Pharm Des 2003 ;9(25):2043-59

GNF - Genomics Institute of the Novartis Research Foundation, Biological Chemistry, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612033454126DOI Listing
February 2004

The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.

Blood 2003 Jan 12;101(2):655-63. Epub 2002 Sep 12.

Klinische Kooperationsgruppe Gentherapie, GSF-National Research Institute for Environment and Health, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-01-0043DOI Listing
January 2003